Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.
The recommendations also apply to biosimilar products of the technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication.
We reviewed the evidence in December 2018. We found nothing new that affects the recommendations in this guidance.
Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.
This guidance replaces NICE technology appraisal guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35).